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The Modification of Diet in Renal Disease (MDRD) 
Study randomized 840 patients, with nondiabetic stage 3 
to 4 chronic kidney disease to a blood pressure of less than 
140/90 mmHg or to a blood pressure of 125/75 mmHg 
(1,2). The blood pressures achieved in this study were 
133/80 mmHg versus 126/77 mmHg. The mean follow-
up was 2.2 years. This study did not show a difference in 
death and in kidney failure between the 2 blood pressure 
groups. However, this study showed that in patients with 
proteinuria greater than 1,000 mg per day, the lower blood 
pressure group had a significant slower rate of decline in 
glomerular filtration rate (1,2). 
The Ramipril Efficacy in Nephropathy (REIN-2) 
trial randomized 338 patients with nondiabetic stage 3 
to 4 chronic kidney disease to a blood pressure of less 
than 140/90 mmHg or to a blood pressure of less than 
130/80 mmHg (3). The blood pressures achieved in this 
study were 134/82 mmHg versus 130/80 mmHg. The 
median follow-up was 1.6 years. This study did not show 
a difference in death and in kidney failure between the 
2 blood pressure groups (3). 
The African American Study of Kidney Disease 
(AASK) trial randomized 1,094 patients with nondiabetic 
hypertensive stage 3 chronic kidney disease to a blood 
pressure of less than 140/90 mmHg or to a blood pressure 
of 125/75 mmHg (4,5). The blood pressures achieved 
in this study were 141/86 versus 130/78 mmHg. The 
median follow-up was 3.8 years. This study did not show a 
difference in death, end-stage renal disease, or a reduction 
in glomerular filtration rate of 50% or more between the 
2 blood pressure groups (4). However, a subanalysis showed 
a reduction in this primary endpoint in patients with 
proteinuria with a protein-to-creatinine ratio of more than 
0.22 (5). 
A meta-analysis of 2,272 patients with nondiabetic 
chronic kidney disease in the AASK, REIN-2, and MDRD 
studies found that the lower blood pressure achieved in 
these 3 trials of 126–130/77–80 mmHg did not improve 
clinical outcomes (6). However, this meta-analysis suggested 
that the lower blood pressure target may be beneficial 
in patients with chronic kidney disease with proteinuria 
greater than 300 to 1,000 mg daily (6). 
On the basis of the available data, the International 
Society of Nephrology 2012 guidelines for treatment of 
blood pressure in patients with non-dialysis-dependent 
chronic kidney disease state that hypertensive patients with 
chronic kidney disease and albuminuria less than 30 mg 
per 24 hours should have their blood pressure lowered to 
less than 140/90 mmHg (7,8). If albuminuria greater than 
30 mg per 24 hours is present, the blood pressure may be 
lowered to less than 130 mm/80 mmHg with a class II D 
indication (7,8).
A meta-analysis reported in 2013 of 11 randomized trials 
in 9287 patients with chronic kidney disease and 1,264 
kidney failure events showed that intensive blood pressure 
lowering reduced the incidence of kidney failure 27% but 
not in patients who did not have baseline proteinuria (9). 
Another meta-analysis  reported in 2013 included 
26 randomized trials with 30,295 patients with chronic 
kidney disease (10). This study showed that compared with 
placebo, blood pressure lowering reduced the incidence of 
major cardiovascular events by approximately a sixth per 
5 mmHg reduction in systolic blood pressure (10). 
A meta-analysis reported in 2016 included 19 randomized 
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trials of 44,989 patients with and without chronic kidney 
disease in whom 2496 major cardiovascular events occurred 
during a mean follow-up of 3.8 years (11). Compared 
to a blood pressure achieved of 140/81, more intensive 
blood pressure lowering to an achieved blood pressure of 
133/76 mmHg reduced major cardiovascular events 14%. 
Absolute reductions in major cardiovascular events were 
greatest in trials in which all enrolled patients had vascular 
disease, chronic kidney disease, or diabetes mellitus (11).
The most important randomized, antihypertensive 
clinical trial comparing a systolic blood pressure goal of 
less than 120 mmHg with a systolic blood pressure goal of 
less than 140 mmHg which included patients with chronic 
kidney disease is the Systolic Blood Pressure Intervention 
Trial (SPRINT) (12,13). This trial included 9,361 patients 
aged 50 years and older with a systolic blood pressure of 
130 mmHg or higher and an increased cardiovascular risk 
but without diabetes mellitus, prior stroke, heart failure, or 
a left ventricular ejection fraction below 35%. The mean 
age was 67.9 years, 28.3% of patients were aged 75 years 
and older, and 28.4% of patients had chronic kidney disease 
with a baseline estimated glomerular filtration rate between 
20 to 59 mL/min/1.73 m2 Automated blood pressures were 
obtained in this study. The mean achieved systolic blood 
pressures at 1 year were 121.4 mmHg in the intensive 
treatment group versus 136.2 mmHg in the standard 
treatment group. The median follow-up was 3.26 years. 
The primary composite endpoint was cardiovascular death, 
myocardial infarction, other acute coronary syndromes, 
heart failure, or stroke. At follow-up, intensive treatment 
of blood pressure reduced the primary outcome 25% and 
all-cause mortality 27% in the entire group (12) and the 
primary outcome 34% and all-cause mortality 33% in the 
group aged 75 years and older (13). In the entire group of 
patients with chronic kidney disease, all-cause mortality 
was reduced 27% from 7.22% with standard blood 
pressure treatment to 5.26% with intensive blood pressure 
treatment (12). The composite renal outcome of first 
occurrence of a reduction in estimated glomerular filtration 
rate of 50% or more, long-term dialysis, or kidney 
transplantation was 1.1% in both blood pressure treatment 
groups. Intensive blood pressure treatment was also 
beneficial in patients with chronic kidney disease who were 
aged 75 years and older including those with frailty or the 
slowest gait speed (13). 
On the basis of the data from SPRINT, the 2016 
Canadian hypertension guidelines recommended lowering 
the systolic blood pressure to 120 mmHg or lower in 
selected high-risk patients such as those with chronic 
kidney disease with an estimated glomerular filtration rate 
between 20 to 59 mL/min/1.73 m2 (14,15). Automated 
blood pressures must be obtained in these patients. I concur 
with automated blood pressure measurements since they are 
more accurate. On the basis of the current available data, I 
favor lowering the blood pressure in patients with chronic 
kidney disease to less than 130/80 mmHg.
Angiotensin-converting enzyme inhibitors, angiotensin 
receptor blockers, beta blockers, calcium channel 
blockers, and thiazide or thiazide-like diuretics are 
effective in reducing cardiovascular events in patients with 
hypertension associated with chronic kidney disease (16,17). 
However, angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers are more effective than other 
antihypertensive drugs in slowing progression of chronic 
kidney disease with proteinuria (18,19). The combined 
use of an angiotensin-converting enzyme inhibitor with an 
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